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Abstract
OBJECTIVE: Previous studies of breast cancer survival have not considered specific depots of 
adipose tissue such as subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT).
METHODS: We assessed these relationships among 3,235 women with stage II/III breast cancer 
diagnosed between 2005–2013 at Kaiser Permanente Northern California and 2000–2012 at the 
Dana Farber Cancer Institute. SAT and VAT areas (cm2) were calculated from routine CT scans 
within 6 (median: 1.2) months of diagnosis, covariates were collected from electronic health 
records, and vital status was assessed by death records. Hazard ratios (HR) and 95% confidence 
intervals (CI) were estimated using Cox regression.
RESULTS: SAT and VAT ranged from 19.0–891 cm2 and 0.484–454 cm2, respectively. SAT was 
related to increased risk of death [127 cm2 increase, HR (95% CI): 1.13 (1.02, 1.26)] but no 
relationship with VAT [78.18 cm2 increase: 1.02 (0.91, 1.14)]. An association with VAT was noted 
among women with stage II cancer [stage II: 1.17 (0.99, 1.39); stage III: 0.90 (0.76, 1.07); p-
interaction: <0.01]. Joint increases in SAT and VAT were associated with mortality above either 
alone [simultaneous 1-SD increase: 1.19 (1.05, 1.34)].
CONCLUSIONS: SAT may be an underappreciated risk factor for breast cancer-related death.
INTRODUCTION
The relationship between excess adiposity and survival among women with breast cancer 
has been widely studied, yet findings have been inconsistent.1–3 Most researchers have 
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considered mortality in relation to body mass index (BMI, kg/m2), a measure of overall body 
size, with several authors noting that among women with breast cancer, the nadir of the 
BMI-mortality relationship can appear to be in the overweight range.3 These findings 
suggest that the ideal weight for breast cancer survivors is greater than that recommended 
for the general population, contributing to confusion around clinical and public health 
messaging.4 These inconsistencies may be due to the fact that weight and BMI are 
inadequate proxies for adiposity that do not distinguish between muscle and adipose tissue, 
nor differentiate specific depots of adipose tissue,5 (e.g. visceral vs. subcutaneous) which 
have different physiological effects.5,6
Fat deposited around the abdominal organs, visceral adipose tissue (VAT), has multiple 
effects. VAT is a source of endogenous estrogen and pro-inflammatory cytokines, and may 
decrease synthesis of sex hormone binding globulin (SHBG).6,7 Furthermore, higher VAT 
has been associated with hyperinsulinemia. Thus, the metabolic environment associated with 
high VAT may encourage tumor progression and negatively influence survival among cancer 
patients.8 In most large epidemiologic studies, VAT is assessed indirectly through 
anthropometric measures of central adiposity,9 such as waist circumference (WC) or waist-
to-hip ratio (WHR). Although some reports have suggested a positive relationship between 
measures of central adiposity and breast cancer-related mortality,10–14 these associations 
have been inconsistent in magnitude, with some reporting only modest relationships12,14 and 
others strong associations.10,11,13 Additionally, the relationship between central adiposity 
and breast cancer survival may be limited to certain subgroups based on menopausal status 
or tumor type.10,14
Although anthropometric measures of central adiposity are positively correlated with VAT, 
they also reflect abdominal subcutaneous adipose tissue (SAT). SAT is adipose tissue stored 
beneath the skin, and appears to be related to a more favorable metabolic profile,9,15 in 
particular SAT stored around the hips and thighs. However, some studies have suggested 
there are notable metabolic differences between SAT stored in the hips and thighs compared 
to the trunk.5 While anthropometric measures of central adiposity do not distinguish 
between abdominal VAT and SAT, imaging techniques such as computed tomography (CT) 
offer more accurate means of assessing the relevant dimensions of adiposity and muscle.
5,9,16
Understanding how specific fat depots are related to breast cancer survival may help to 
clarify the relationship between excess adiposity and mortality, and more accurately identify 
patients at high risk of death, than using weight or BMI alone. However, few studies have 
considered direct measures of VAT vs. SAT and, to our knowledge, none have focused on 
women with non-metastatic breast cancer. Although a recent paper from our group reported 
that increased total adiposity and low muscle mass measured by CT scans is associated with 
poorer survival, and outperforms BMI, that analysis did not distinguish between SAT and 
VAT depots.17 In the current study, we consider the relationships between CT-derived 
measures of SAT and VAT on overall mortality in a large cohort of women recently 
diagnosed with non-metastatic breast cancer.
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METHODS
Study Population
Our analysis used data from the Breast Cancer-Sarcopenia and Near Term Survival (B-
SCANS) cohort study, derived from electronic medical record data from Kaiser Permanente 
Northern California (KPNC) and Dana Farber Cancer Institute (DFCI). This study included 
women older than 18 years of age, with no prior history of cancer, who were diagnosed with 
stage II or III invasive breast cancer and had an abdominal or pelvic computed tomography 
(CT) scan within 6 months of diagnosis and prior to any chemotherapy or radiation therapy 
(n=3,706). Subjects from KPNC included those members diagnosed between 2005–2013 
and data from DFCI included patients diagnosed between 2000 and 2012. Exclusions in the 
total cohort included 303 patients without a valid weight measure around the CT scan, 120 
patients whose scans were either unavailable or unreadable due to image quality issues, and 
42 patients with BMI < 18.5 at time of scan. We also excluded 23 women with missing data 
on race, 11 with missing surgery type and 7 with missing ER or PR status. This left 3,235 
patients in the final analytic sample. Vital status data for KPNC members was verified from 
various sources, including the electronic medical record, California state death records, or 
Social Security Death Index, and for DFCI patients from the electronic medical record and 
the National Death Index. The study was approved by the KPNC and DFCI institutional 
review boards.
Body Composition Assessment
Body composition measures were assessed by centrally trained researchers from CT scans 
obtained during routine clinical care, using the scan that was taken within six months and 
nearest to diagnosis, and prior to chemotherapy or radiation treatment (median: 1.2 months, 
range: ±5.9 months). Our analysis did not include stage I patients because they do not 
routinely receive CT scans, and thus those who did might be a non-representative sample of 
those patients. From the CT scan, we measured body composition at the third lumbar 
vertebra (L3), and calculated cross-sectional area in centimeters squared (cm2) of adipose 
tissue (SAT, VAT) and skeletal muscle index (SMI, cm2 from rectus abdominus, erector 
spinae muscles, quadratus lumborum, psoas, and internal, transverse and external oblique 
muscle groups divided by height in m2) by tissue-specific Hounsfield Unit ranges using 
SliceOmatic Software version 5.0 (TomoVision, Montreal, Quebec, Canada).18 These 
quantities have been previously shown to be valid proxies for whole body volumes of muscle 
and adipose tissue.19 The coefficients of variation (CV%) for 30 images randomly selected 
and colored by both readers were 0.79 and 6.72, and 0.66, for SAT, VAT, and SMI, 
respectively.
Covariate Assessment
Data on relevant covariates, including demographic characteristics, height, weight, disease 
stage, tumor characteristics, smoking, and treatment were obtained from the medical records 
or Cancer Registry. For height and weight, we used the measurement at the clinical visit 
closest to the scan [mean (range), 0.0 (−5.8 to 3.3) months].
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Statistical Analysis
We report counts and percentages, and means and standard deviations, for categorical and 
continuous characteristics, respectively, by groups defined by quartiles of subcutaneous and 
visceral fat among those who died. We also calculated Kaplan-Meier survival functions over 
the follow-up separately for these groups. Follow-up time accrued beginning at the time of 
CT scan and continued until the earlier of: 1) death from any cause, or 2) July 15, 2016 
(KPNC cohort) or last date of contact (DFCI cohort), the latter for censored observations. 
Median follow-up time was 6.30 years (range 0.041–12.6 years) for the KPNC cohort and 
8.5 years (range 0.27–16.5 years) for the DFCI group. Hazard ratios (HR) and 95% 
confidence intervals (CI) were estimated with Cox proportional hazards models allowing for 
left truncation with baseline hazard stratified by study site. Because there are no established 
cutpoints for these measures of body composition, we considered SAT and VAT as 
continuous variables. To allow for nonlinear relationships between adiposity measures and 
mortality we expressed them with restricted quadratic spline coding and evaluated 
nonlinearity with the likelihood ratio test of the higher order spline terms.20 Knot points for 
each variable were at quartiles of its distribution among those who died in order to allow for 
sufficient number of events in each region. All models included both measures of adiposity 
and were additionally adjusted for potential confounders determined from a directed acyclic 
graph from those variables believed to be associated with body composition and mortality 
and not lie on the causal pathway between the exposures and outcome: age at diagnosis 
(continuous, restricted quadratic spline with knots at quintiles), smoking status, race, tumor 
grade, surgery, estrogen- or progesterone-receptor (ER/PR) status, HER-2 status, skeletal 
muscle area (continuous), and the portion of BMI not included in muscle or fat (continuous). 
Treatment modalities were not considered as potential confounders given the timing of the 
CT scan preceded treatment for most women, and thus it could not influence body 
composition. The nonlinear spline terms for SAT and VAT did not achieve statistical 
significance (p-nonlinearity, SAT: 0.59; VAT: 0.36) so we present models with these 
variables expressed linearly in the log-hazard scaled to represent a 1-standard deviation (1-
SD) increase in the corresponding measure. Effect modification was examined through Wald 
tests on the multiplicative interaction term. We considered the potential for these 
associations to vary across site through interaction terms between each body fat measure and 
site. Since body composition near diagnosis could reflect the consequences of more 
aggressive disease, thus making it appear that low body fat is related to increased risk for 
death close to diagnosis, we evaluated interactions between each body composition variable 
and an indicator that follow-up time was >1 years post diagnosis. We also evaluated 
heterogeneity between SAT and VAT associations over levels of age (dichotomized as <55 
years vs. ≥ 55 years), stage (II vs. III), low muscle mass (defined as muscle area divided by 
squared height in meters < 40), ER/PR status (negative vs. positive), and Her-2 status 
(negative/indeterminate vs. positive) in separate models. Age was dichotomized at 55 years 
as a proxy for menopausal status, which was not available from the medical record. We also 
considered the joint effects of SAT and VAT by the multiplicative interaction between these 
variables, reporting associations for 1-SD increases in these variables relative to their mean 
value.
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Cause of death was not available for the DFCI portion of the cohort, but we additionally 
considered these relationships with regard to breast cancer specific mortality in the KPNC 
sample. Cause-specific hazard ratios were estimated by censoring those subjects who died 
from causes other than breast cancer, as well as those alive at the end of follow-up in the 
KPNC sample (July 15, 2016).
All analyses were performed using R statistical software.21 Statistical significance was 
established with 2-sided tests with 0.05 significance level.
RESULTS
Characteristics of the study population are presented in Table 1. Among the 3,235 women 
included in our analysis, 708 died over the follow-up. Individuals in the lower quartiles of 
SAT, and particularly VAT, were younger than those in the upper categories. Those with 
higher SAT were more likely to be African-American and less likely to be Asian or Pacific 
Islander than those with lower SAT. Conversely, individuals with greater VAT were more 
likely to be Hispanic than those with less VAT. Those with stage III disease tended to have 
higher levels of both measures of adiposity (mean SAT stage II: 239.6 cm2, stage III: 256.8 
cm2; mean VAT stage II: 95.5 cm2, stage III: 105.1 cm2) and to have similar amounts of 
muscle mass (mean SMI stage II: 43.2 cm2/m2; stage III, 43.7 cm2/m2). Positive ER/PR 
tumor status was more common among those with greater VAT, but was similar across 
quartiles of SAT. The unadjusted Kaplan-Meier curves (Figure 1) illustrate a lower 
probability of survival among those with 336–891 cm2 (highest quartile) SAT (panel A) and 
with 163–454 cm2 (highest quartile) VAT (panel B), with similar survival among the other 
groups defined by quartiles of each variable. The correlation between SAT and VAT was 
0.61.
After adjusting for patient and tumor characteristics, a 1-SD (126.99 cm2) increase in SAT 
was associated with greater risk of death from any cause [HR: 1.13 (1.02, 1.26)], while a 1-
SD (78.18 cm2) increase in VAT was not [HR: 1.02 (0.91, 1.14)] (Table 2). These 
relationships appeared to be consistent across study site (p-interaction, SAT: 0.71, VAT: 
0.60) and over the follow-up period (p-interaction with >1 year follow-up time indicator, 
SAT: 0.97, VAT: 0.52). Associations between both SAT and VAT and mortality were also 
similar across categories of age (p-interaction, SAT: 0.54, VAT: 0.14), muscle area (p-
interaction, SAT: 0.73, VAT: 0.50), ER/PR status (p-interaction, SAT: 0.49, VAT: 0.84), and 
HER-2 status (p-interaction, SAT: 0.67, VAT: 0.93), as was the SAT-mortality association 
across stage (p-interaction: 0.22). However, there was evidence of heterogeneity of the VAT-
mortality relationship by stage (p-value: <0.01), with a steeper positive relationship between 
VAT and mortality among those classified as stage II [per 78.18 cm2 increase in VAT, HR: 
1.17 (0.99, 1.39)] compared to a slight inverse relationship among those classified as stage 
III [HR: 0.90 (0.76, 1.07)]. The relationships between SAT, VAT and breast cancer-specific 
mortality in the KNPC portion of the cohort are presented in Table 3. Associations were 
generally similar in magnitude but estimates were less precise due to the reduced number of 
events when restricting to specific causes of death among a subset of the study sample. We 
did not observe evidence of heterogeneity of the association between SAT or VAT and breast 
cancer-specific mortality by any of the covariates considered.
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As shown in Table 4, there was a suggestion of a synergistic effect between SAT and VAT 
for all-cause mortality (p-interaction: 0.04). Hazard ratios for individual changes in SAT and 
VAT from the model that included the multiplicative interaction were of similar magnitude 
to the main effects model [1-SD increase in SAT alone HR: 1.12 (0.99, 1.27); per 1-SD 
increase in VAT alone: 0.99 (0.87, 1.14)], but we observed a somewhat greater than 
multiplicative effect for increases in both measures simultaneously [HR: 1.19 (1.05, 1.34)]. 
When considering breast cancer-specific deaths, we did not observe evidence of interaction 
between SAT and VAT (p-interaction: 0.46).
DISCUSSION
To our knowledge this is the first analysis to consider the independent and synergistic effects 
of specific fat depots in relation to survival in a large sample of women with non-metastatic 
breast cancer. We demonstrated that in addition to considering total adiposity, assessment of 
individual fat depots will provide key clinical information. Contrary to our a priori 
hypothesis, we found that elevated SAT was associated with worse survival among all 
women, but a deleterious relationship with VAT was only observed for women with stage II 
cancer.
To date, few researchers have considered the relationship between SAT and cancer-related 
mortality, but a recent study of 1,746 patients with gastrointestinal, respiratory, or kidney 
cancers reported that low SAT was related to poor survival.22 However, that analysis did not 
include any breast cancer patients, and the majority of the patients in that study had 
advanced stage disease. In contrast to our results, a small study of 172 women with 
metastatic breast cancer failed to find an association between SAT and mortality.23 
Compared to the limited prior research on SAT, the relationship between VAT and mortality 
has been considered more frequently. According to a recent review of 22 studies of CT 
determined VAT and cancer survival, greater VAT tended to be associated with poor survival 
among those with colorectal and pancreatic cancers, but improved survival among those with 
kidney cancer.24 However, our observation that greater VAT was related to poor survival 
among only women with stage II, but not stage III, breast cancer is not corroborated by the 
only report among women with breast cancer, limited to those with advanced stage disease, 
that found an positive association between VAT and mortality.23
Our findings suggest that elevated SAT, in particular that around the abdomen, may be an 
underappreciated risk factor for mortality among women with breast cancer. Although CT 
imaging has been shown to be well-correlated with total body volumes of subcutaneous and 
visceral adipose tissue,25 scans at the L3 vertebra, which we used for this analysis, would 
capture SAT in the trunk, specifically the abdomen, more than other areas. Greater 
abdominal SAT may reflect a phenotype with unique effects in the breast as abdominal SAT 
is correlated with breast adipose tissue more strongly than either VAT or gluteofemoral SAT.
26,27
 Breast adipose tissue is a site for crown-like structures of the breast (CLS-B), 
macrophage-infiltrated adipocytes which produce a milieu of inflammatory cytokines and 
encourage endogenous estrogen production,28 which provide an environment thought to 
encourage tumor growth and development. Besides the local influences of CLS-B, research 
has also shown that even among ideal weight women (18.5 ≤ BMI < 25), CLS-B are 
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associated with systemic metabolic dysfunction, including higher circulating leptin, insulin 
and triglycerides29 which could also influence survival.
Another potential explanation is that SAT in the trunk, particularly around the abdomen, 
appears to have different systemic metabolic effects compared to SAT in the gluteofemoral 
region.30 SAT in the gluteofemoral region is homogeneous, and related to a relatively 
favorable metabolic profile,30 but abdominal SAT may have metabolic effects similar to, and 
independent from, VAT.31 These observations may be explained by the different sub-depots 
of abdominal SAT, which may be separated into compartments that are anterior and posterior 
to the fascia superficialis: superficial SAT (sSAT) and deep SAT (dSAT), respectively.32,33 
These sub-depots differ in their fatty acid composition34 as well as their anatomic location. 
Abdominal sSAT is metabolically more similar to gluteofemoral SAT than dSAT or VAT as 
it has less potential for insulin resistance than other depots.35 Conversely, researchers have 
demonstrated that dSAT has systemic effects similar to VAT.32,35 Thus, SAT around the 
abdomen may influence tumor promotion and cancer survival through mechanisms similar 
to those related to VAT.
VAT is often cited as the relevant fat depot in disease etiology because of its systemic effects 
on hyperinsulinemia, inflammation, and endogenous estrogen synthesis.36,37 We observed a 
trend toward greater risk of death with increasing levels of VAT only among women with 
stage II disease, but a slightly lower risk of death with increasing VAT among women with 
stage III disease. The opposite pattern was observed for SAT, with a somewhat more 
pronounced association among women with advanced stage disease. The potential 
mechanism for these observations is unclear, and additional research should seek to clarify 
this finding. In contrast to our previous results regarding overall adiposity,17 we did not find 
evidence of heterogeneity of the association of either of these specific fat measures 
according to level of muscle area. Low muscle mass is independently related to poor insulin 
sensitivity38 and inflammation,39 and has been linked to poor survival.17,40 The findings 
from our two studies taken together may suggest that in the presence of low muscle, the 
overall burden of body fat may be more important than the effect of either of the adipose 
tissue compartments individually.
Strengths of our study include a large sample size with long-term follow-up using resources 
from two large healthcare systems, allowing for detailed characterization of patient-level and 
tumor data. Importantly, we were able to use clinically-derived CT scans to assess measures 
of specific aspects of body composition that had not been previously considered in relation 
to breast cancer mortality, instead of more gross anthropometric measures such as waist 
circumference or BMI. However, our analysis has a few limitations. First, our analysis relied 
on cross-sectional CT images at the L3 vertebra to assess body composition which may 
reflect adipose tissue in a single anatomical area rather than whole-body volumes. This may 
have resulted in some mis-characterization of body composition since it does not capture the 
total volume in each region, and does not include adiposity in certain areas, such as around 
the hips and thighs. However, prior studies have shown assessments from scans at the L3 
vertebra to be reasonable proxies of overall body composition.19 We note that the CV for the 
agreement of VAT area across readers was somewhat higher than for SAT in our data, which 
could suggest some potential for greater measurement error in VAT. However, mean VAT 
Bradshaw et al. Page 7
Obesity (Silver Spring). Author manuscript; available in PMC 2019 October 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
area is much lower than mean SAT, thus errors of similar absolute magnitude would yield 
larger CVs for the former. Nevertheless, the CV for both measures was low, indicating good 
agreement between readers. Additionally, our study used single assessments of body 
composition which would not capture its longitudinal trajectory over the follow-up period. 
Clarifying how changes and trends in body composition are related to mortality among 
breast cancer survivors would provide important insight. We did not have data on cause of 
death in the DFCI group, which precluded us from considering breast-cancer specific 
mortality. Finally, although we adjusted for tumor characteristics and stage of disease we 
cannot rule out the possibility that these associations could be a consequence of disease 
progression and not causal.
CONCLUSION
CT-scans are routinely performed in clinical care of cancer patients, and thus these measures 
of body composition are easily obtained and provide a more refined measure of obesity than 
BMI. In addition to providing improved prognostic indicators, aspects of body composition 
may yield new insight the relationship between adiposity and cancer-related mortality. Our 
findings regarding the relationship between specific adipose tissue depots and survival 
among women with breast cancer suggests that there may be distinct relationships between 
mortality and abdominal SAT and VAT. Future work should aim to clarify the relationship 
between abdominal SAT, breast adipose tissue, and mortality. If abdominal SAT is, in fact, a 
marker of breast adipose tissue and CLS-B infiltration, then CT-assessments of abdominal 
SAT may be useful to identify women for whom interventions to ameliorate the 
inflammatory effects of excess breast adipose tissue would be most beneficial.
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What is already known about this subject?
• The relationship between body mass index (BMI) and cancer survival has 
been inconsistent.
• Specific adipose tissue depots may have different relationships with mortality 
but measures of overall adiposity are unable to distinguish them.
• Measures of body composition from computed tomography (CT) scans offer 
an opportunity to clarify the relationship between adipose tissue depots and 
cancer survival.
What does this study add?
• Among women with nonmetastatic breast cancer, subcutaneous adipose tissue 
(SAT) appears to be associated with greater overall mortality, independent of 
other measures of body composition.
• In stratified analyses, greater VAT was related to poorer survival only among 
women with earlier stage disease.
• There appears to be a synergistic effect between increases in SAT and VAT 
and overall mortality.
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Figure 1. 
Kaplan-Meier curves for the relationship between subcutaneous adipose tissue (panel A), 
visceral adipose tissue (panel B) and mortality.
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